805 related articles for article (PubMed ID: 24142395)
21. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.
Ito H; Abramson M; Ito K; Swanson E; Cho N; Ruan DT; Swanson RS; Whang EE
J Gastrointest Surg; 2010 May; 14(5):891-8. PubMed ID: 20224984
[TBL] [Abstract][Full Text] [Related]
22. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
23. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
26. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
28. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
29. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
[TBL] [Abstract][Full Text] [Related]
31. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
34. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
35. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
36. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
[TBL] [Abstract][Full Text] [Related]
37. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
39. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
40. The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.
Sugimoto S; Hotta K; Shimoda T; Imai K; Yamaguchi Y; Nakajima T; Oishi T; Mori K; Takizawa K; Kakushima N; Tanaka M; Kawata N; Matsubayashi H; Ono H
Surg Endosc; 2016 Oct; 30(10):4239-48. PubMed ID: 26718357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
